Sequential Bolus Administration of rIL-2 (RU 49637) in Treatment of Advanced Solid Malignancies
The use of recombinant interleukin-2 (rIL-2) is under intensive investigation since promising reports have shown high activity in patients with refractory neoplasias . Recombinant technology permits the development of different recombinant molecules, the activity of which are difficult to compare. Biological tests are insufficient at the present time to give adequate comparison of clinical activity of these molecules. It was necessary to conduct clinical trials to determine the maximum tolerable dose (MTD) which can be administrated to patients with a reasonable toxicity as efficacity is related to the maximum exposure to RIL-2. Most of the reported trials used combinations of rIL-2 and cellulotherapy for diseases previously shown to be sensitive to immunotherapy [3, 4]. New strategies using different administration schedules or cytokine combinations without stimulation of cells in vitro may be a lighter and more efficient approach. In this phase 1 trial we determined MTD of RU 49637 by sequential delivery over 34 days.
KeywordsToxicity Dopamine Corticosteroid Shrinkage Sarcoma
Unable to display preview. Download preview PDF.
- 1.Creekmore S, Harris J, Ellis T, Braun D, Cohen I, Bhoopalam N, Jassak P, Cahill M, Canzoreni C, Fisher R (1989) A phase 1 clinical trial of recombinant IL2 by periodic 24-H intravenous infusions. JCO 7 (2):276–284Google Scholar
- 3.Rosenberg SA, Lotze PMT, Muul LM, Chang AE, Avis FP, Leitman S, Lineham WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson G, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 or high dose interleukin 2 alone. N Engl J Med 316 (15):889–897PubMedCrossRefGoogle Scholar
- 4.Rosenberg S, Packard B, Aelbersold P, Salomon D, Topalian S, Toy S, Simon P, Lotze M, Yang J, Seipp C, Simpson C, Carter C, Bock S, Schwartzenbruter D, Wei J, White D (1988) Use of tumor infiltrating lymphocytes and IL2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 25:1676–1680CrossRefGoogle Scholar